CN101998992A - 用于治疗、诊断和测试的涉及ms4a12之方法以及靶向ms4a12之试剂 - Google Patents

用于治疗、诊断和测试的涉及ms4a12之方法以及靶向ms4a12之试剂 Download PDF

Info

Publication number
CN101998992A
CN101998992A CN2009801128194A CN200980112819A CN101998992A CN 101998992 A CN101998992 A CN 101998992A CN 2009801128194 A CN2009801128194 A CN 2009801128194A CN 200980112819 A CN200980112819 A CN 200980112819A CN 101998992 A CN101998992 A CN 101998992A
Authority
CN
China
Prior art keywords
ms4a12
cell
egf
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801128194A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔·沙欣
厄兹莱姆·图雷奇
米夏埃尔·科斯洛夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg University Of Mainz
Ganymed Pharmaceuticals GmbH
Original Assignee
Johannes Gutenberg University Of Mainz
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg University Of Mainz, Ganymed Pharmaceuticals GmbH filed Critical Johannes Gutenberg University Of Mainz
Publication of CN101998992A publication Critical patent/CN101998992A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801128194A 2008-04-10 2009-03-30 用于治疗、诊断和测试的涉及ms4a12之方法以及靶向ms4a12之试剂 Pending CN101998992A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08007109.5 2008-04-10
EP08007109A EP2108701A1 (en) 2008-04-10 2008-04-10 Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
PCT/EP2009/002309 WO2009124670A1 (en) 2008-04-10 2009-03-30 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing

Publications (1)

Publication Number Publication Date
CN101998992A true CN101998992A (zh) 2011-03-30

Family

ID=39811474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801128194A Pending CN101998992A (zh) 2008-04-10 2009-03-30 用于治疗、诊断和测试的涉及ms4a12之方法以及靶向ms4a12之试剂

Country Status (8)

Country Link
US (1) US20110027297A1 (enExample)
EP (2) EP2108701A1 (enExample)
JP (1) JP2011520781A (enExample)
CN (1) CN101998992A (enExample)
AU (1) AU2009235746A1 (enExample)
CA (1) CA2714997A1 (enExample)
NZ (1) NZ588177A (enExample)
WO (1) WO2009124670A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250378A (zh) * 2015-02-24 2017-10-13 株式会社遗传科技 癌的脑转移的诊断、预防及治疗方法、以及用于通过血脑屏障的药物传输系统
CN109562379A (zh) * 2016-06-20 2019-04-02 拜克门寇尔特公司 用于染料共轭试剂的干燥过程
CN114341181A (zh) * 2019-07-31 2022-04-12 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
US12215149B2 (en) 2018-01-31 2025-02-04 Alector Llc Anti-MS4A6A antibodies and methods of use thereof
US12331112B2 (en) 2018-01-31 2025-06-17 Alector Llc Anti-MS4A4A antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250378A (zh) * 2015-02-24 2017-10-13 株式会社遗传科技 癌的脑转移的诊断、预防及治疗方法、以及用于通过血脑屏障的药物传输系统
CN107250378B (zh) * 2015-02-24 2021-09-03 特里奥科技株式会社 癌的脑转移的诊断、预防及治疗方法、以及用于通过血脑屏障的药物传输系统
CN109562379A (zh) * 2016-06-20 2019-04-02 拜克门寇尔特公司 用于染料共轭试剂的干燥过程
US11249075B2 (en) 2016-06-20 2022-02-15 Beckman Coulter, Inc. Dry-down processes for dye-conjugated reagents
US11774443B2 (en) 2016-06-20 2023-10-03 Beckman Coulter, Inc. Dry-down processes for dye-conjugated reagents
US12215149B2 (en) 2018-01-31 2025-02-04 Alector Llc Anti-MS4A6A antibodies and methods of use thereof
US12331112B2 (en) 2018-01-31 2025-06-17 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
US12331111B2 (en) 2018-01-31 2025-06-17 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
CN114341181A (zh) * 2019-07-31 2022-04-12 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
CN114341181B (zh) * 2019-07-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法

Also Published As

Publication number Publication date
EP2108701A1 (en) 2009-10-14
WO2009124670A1 (en) 2009-10-15
JP2011520781A (ja) 2011-07-21
US20110027297A1 (en) 2011-02-03
AU2009235746A1 (en) 2009-10-15
EP2265718A1 (en) 2010-12-29
NZ588177A (en) 2012-06-29
CA2714997A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
US20210355495A1 (en) Methods to eliminate cancer stem cells by targeting cd47
US8168586B1 (en) Cancer targets and uses thereof
KR102340685B1 (ko) 암의 진단 및 치료를 위한 방법 및 조성물
WO2008011519A2 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
JP5590693B2 (ja) がん患者の予後推定用バイオマーカー及びその利用
CN101998992A (zh) 用于治疗、诊断和测试的涉及ms4a12之方法以及靶向ms4a12之试剂
US9061007B2 (en) Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
US20190177727A1 (en) Methods for diagnosing and treating metastatic cancer
JP2009523409A (ja) がん治療用およびがん診断用の組成物および方法
JP4797159B2 (ja) 癌転移抑制用組成物
AU2007306598B2 (en) Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
KR20140042577A (ko) 암의 예후 예측 및 치료를 위한 ｍａｅｌ의 용도
Anderson Parathyroid hormone-related peptide: a key factor in cell adhesion
WO2006020557A2 (en) Methods of using or identifying agents that inhibit cancer growth
WO2014043331A2 (en) Specific phospho-forms of elk-1 as biomarkers and therapeutic targets for cancer
JP2011105669A (ja) 抗腫瘍剤および抗腫瘍剤のスクリーニング方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110330